Multicenter Retrospective Study of Isoflurane in Refractory and Super-Refractory Status Epilepticus

Isoflurane might be used as anticonvulsive therapy in refractory status epilepticus. The aim of the study is to assess the efficiency of Isoflurane in this indication.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Refractory Status Epilepticus Nervous System Diseases Neurologic Manifestations Pathological Conditions, Signs and Symptoms Seizures Signs and Symptoms Status Epilepticus

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Ch Bethune Beuvry, Beuvry, France

About this study

Investigators will collect in 4 ICUs the data from consecutive patients hospitalized between january 2016 and january 2023. Included patient were those treated by Isoflurane for refractory status epilepticus.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age > 18 years, hospitalized in ICU between 2016-01-01 and 2023-01-01, suffering refractory status epilepticus treated by inhaled Isoflurane as third anticonvulsive therapy

Exclusion criteria

post-anoxic refractory status epilepticus after cardiac arrest, withdrawal of consent for medical data use

Treatment and study plan

Isoflurane

Drug

no other intervention

Primary outcomes

rate of crisis control

Time frame: 3 months

rate of patients with crisis control or complete awakening

Sponsors and collaborators

Lead sponsor

Hopital of Melun

Other

Registry information

Official study title

Multicenter Retrospective Study of Isoflurane in Refractory and Super-Refractory Status Epilepticus (I-Seizure)

Acronym: I-Seizure

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2025
First posted: Apr 26, 2023
Registry last updated: Sep 26, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed